$331M deal: GSK sells rights to experimental psoriasis drug

Under the terms of the $331 million deal Dermavant, a Durham, N.C., subsidiary of Roivant Sciences, agreed to pay GSK $199 million upfront and … …read more

Read more here:: $331M deal: GSK sells rights to experimental psoriasis drug